FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149210345> ?p ?o ?g. }

• W2149210345 endingPage "253" @default.
• W2149210345 startingPage "243" @default.
• W2149210345 abstract "We designed a phase I/II trial in order to evaluate the efficacy and tolerability of induction carboplatin and gemcitabine and the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of subsequent chemoradiotherapy with weekly vinorelbine and paclitaxel in patients with stage III non-small cell lung cancer (NSCLC).Patients had pathologically confirmed N2-N3 stage NSCLC, adequate end-organ function, and ECOG performance status 0-2. Carboplatin was administered at an AUC of 5 on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8, every 21 days, for two cycles, followed by weekly vinorelbine 10-15 mg/m2 and paclitaxel 50 mg/m2 and conventional chest radiotherapy up to 66 Gy. Patients with resectable disease underwent thoracotomy after 40-45 Gy.Thirty-nine eligible patients were enrolled; 17 had stage IIIB NSCLC. Grade 3 esophagitis developed in 4/5 patients on the second dose level of chemoradiotherapy (i.e. vinorelbine 15 mg/m2) and was considered dose-limiting. Of 34 patients treated at the maximum tolerated dose (i.e. vinorelbine 10 mg/m2), 2 patients (6%) had pneumonitis >grade 2 and 3 (9%), esophagitis >grade 2. Induction chemotherapy was well tolerated with only one patient developing >grade 2 non-hematologic toxicity (nausea). Forty-one percent of patients had an objective response after induction chemotherapy and 51% after chemoradiotherapy. Nineteen patients, 16 of whom had stage IIIA, underwent surgical resection. The pathologic complete response rate was 16% (42% in the mediastinal lymph nodes). With a median follow-up of 31 months, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 23 and 34%, respectively, and the median OS was 25 months.We identified a well-tolerated and active chemoradiotherapy regimen. Survival results are promising and the addition of a biologic agent to this regimen is of interest." @default.
• W2149210345 created "2016-06-24" @default.
• W2149210345 creator A5008924495 @default.
• W2149210345 creator A5017187936 @default.
• W2149210345 creator A5039680305 @default.
• W2149210345 creator A5060368886 @default.
• W2149210345 creator A5064571561 @default.
• W2149210345 creator A5071796883 @default.
• W2149210345 creator A5081097197 @default.
• W2149210345 date "2004-08-01" @default.
• W2149210345 modified "2023-09-25" @default.
• W2149210345 title "A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer" @default.
• W2149210345 cites W1751540033 @default.
• W2149210345 cites W1817196311 @default.
• W2149210345 cites W1855747096 @default.
• W2149210345 cites W1870429510 @default.
• W2149210345 cites W1944220675 @default.
• W2149210345 cites W1973641691 @default.
• W2149210345 cites W1979300931 @default.
• W2149210345 cites W1984288851 @default.
• W2149210345 cites W1986794774 @default.
• W2149210345 cites W1993312546 @default.
• W2149210345 cites W2001565720 @default.
• W2149210345 cites W2008765859 @default.
• W2149210345 cites W2012346354 @default.
• W2149210345 cites W2014145691 @default.
• W2149210345 cites W2020933083 @default.
• W2149210345 cites W2024219304 @default.
• W2149210345 cites W2038954195 @default.
• W2149210345 cites W2047461796 @default.
• W2149210345 cites W2055386757 @default.
• W2149210345 cites W2057157978 @default.
• W2149210345 cites W2060985892 @default.
• W2149210345 cites W2088620522 @default.
• W2149210345 cites W2091053660 @default.
• W2149210345 cites W2103027616 @default.
• W2149210345 cites W2104325484 @default.
• W2149210345 cites W2105024669 @default.
• W2149210345 cites W2109694492 @default.
• W2149210345 cites W2116996913 @default.
• W2149210345 cites W2131928292 @default.
• W2149210345 cites W2144896405 @default.
• W2149210345 cites W2155709777 @default.
• W2149210345 cites W2157659361 @default.
• W2149210345 cites W2159324698 @default.
• W2149210345 cites W2162112471 @default.
• W2149210345 cites W2162328883 @default.
• W2149210345 cites W2176864701 @default.
• W2149210345 cites W2204625425 @default.
• W2149210345 cites W2257430737 @default.
• W2149210345 cites W2261464614 @default.
• W2149210345 cites W2278556698 @default.
• W2149210345 cites W2317448174 @default.
• W2149210345 cites W2411198830 @default.
• W2149210345 cites W2474438615 @default.
• W2149210345 cites W2607182122 @default.
• W2149210345 cites W3040906735 @default.
• W2149210345 cites W2143110862 @default.
• W2149210345 doi "https://doi.org/10.1016/j.lungcan.2004.02.008" @default.
• W2149210345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15246197" @default.
• W2149210345 hasPublicationYear "2004" @default.
• W2149210345 type Work @default.
• W2149210345 sameAs 2149210345 @default.
• W2149210345 citedByCount "10" @default.
• W2149210345 crossrefType "journal-article" @default.
• W2149210345 hasAuthorship W2149210345A5008924495 @default.
• W2149210345 hasAuthorship W2149210345A5017187936 @default.
• W2149210345 hasAuthorship W2149210345A5039680305 @default.
• W2149210345 hasAuthorship W2149210345A5060368886 @default.
• W2149210345 hasAuthorship W2149210345A5064571561 @default.
• W2149210345 hasAuthorship W2149210345A5071796883 @default.
• W2149210345 hasAuthorship W2149210345A5081097197 @default.
• W2149210345 hasConcept C126322002 @default.
• W2149210345 hasConcept C141071460 @default.
• W2149210345 hasConcept C143998085 @default.
• W2149210345 hasConcept C2776256026 @default.
• W2149210345 hasConcept C2776611710 @default.
• W2149210345 hasConcept C2776694085 @default.
• W2149210345 hasConcept C2778239845 @default.
• W2149210345 hasConcept C2778424827 @default.
• W2149210345 hasConcept C2779134260 @default.
• W2149210345 hasConcept C2779920096 @default.
• W2149210345 hasConcept C2780258809 @default.
• W2149210345 hasConcept C2780350996 @default.
• W2149210345 hasConcept C2781451048 @default.
• W2149210345 hasConcept C43270747 @default.
• W2149210345 hasConcept C71924100 @default.
• W2149210345 hasConcept C90924648 @default.
• W2149210345 hasConceptScore W2149210345C126322002 @default.
• W2149210345 hasConceptScore W2149210345C141071460 @default.
• W2149210345 hasConceptScore W2149210345C143998085 @default.
• W2149210345 hasConceptScore W2149210345C2776256026 @default.
• W2149210345 hasConceptScore W2149210345C2776611710 @default.
• W2149210345 hasConceptScore W2149210345C2776694085 @default.
• W2149210345 hasConceptScore W2149210345C2778239845 @default.
• W2149210345 hasConceptScore W2149210345C2778424827 @default.
• W2149210345 hasConceptScore W2149210345C2779134260 @default.
• W2149210345 hasConceptScore W2149210345C2779920096 @default.

• next